Activators and inhibitors of NRF2: a review of their potential for clinical development

N Robledinos-Antón… - Oxidative medicine …, 2019 - Wiley Online Library
The transcription factor NRF2 (nuclear factor erythroid 2‐related factor 2) triggers the first
line of homeostatic responses against a plethora of environmental or endogenous …

Glycogen synthesis and beyond, a comprehensive review of GSK3 as a key regulator of metabolic pathways and a therapeutic target for treating metabolic diseases

L Wang, J Li, L Di - Medicinal Research Reviews, 2022 - Wiley Online Library
Abstract Glycogen synthase kinase‐3 (GSK3) is a highly evolutionarily conserved
serine/threonine protein kinase first identified as an enzyme that regulates glycogen …

Glycogen synthase kinase-3 inhibitors: preclinical and clinical focus on CNS-A decade onward

SM Arciniegas Ruiz, H Eldar-Finkelman - Frontiers in molecular …, 2022 - frontiersin.org
The protein kinase, GSK-3, participates in diverse biological processes and is now
recognized a promising drug discovery target in treating multiple pathological conditions …

GSK-3β, FYN, and DYRK1A: master regulators in neurodegenerative pathways

S Demuro, RMC Di Martino, JA Ortega… - International journal of …, 2021 - mdpi.com
Protein kinases (PKs) have been recognized as central nervous system (CNS)-disease-
relevant targets due to their master regulatory role in different signal transduction cascades …

Mechanisms and therapeutic implications of GSK-3 in treating neurodegeneration

I Rippin, H Eldar-Finkelman - Cells, 2021 - mdpi.com
Neurodegenerative disorders are spreading worldwide and are one of the greatest threats to
public health. There is currently no adequate therapy for these disorders, and therefore there …

Tau-centric multitarget approach for Alzheimer's disease: development of first-in-class dual glycogen synthase kinase 3β and tau-aggregation inhibitors

A Gandini, M Bartolini, D Tedesco… - Journal of medicinal …, 2018 - ACS Publications
Several findings propose the altered tau protein network as an important target for
Alzheimer's disease (AD). Particularly, two points of pharmacological intervention can be …

Glycogen synthase kinase-3 and its inhibitors: Potential target for various therapeutic conditions

AP Saraswati, SMA Hussaini, NH Krishna… - European journal of …, 2018 - Elsevier
Abstract Glycogen Synthase Kinase-3 (GSK-3) is a serine/threonine kinase which is
ubiquitously expressed and is regarded as a regulator for various cellular events and …

Glycogen synthase kinases: Moonlighting proteins with theranostic potential in cancer

S Nagini, J Sophia, R Mishra - Seminars in cancer biology, 2019 - Elsevier
Abstract Glycogen synthase kinase-3 (GSK-3), a serine/threonine kinase is an archetypal
multifunctional moonlighting protein involved in diverse cellular processes including …

[HTML][HTML] Crosstalks of GSK3 signaling with the mTOR network and effects on targeted therapy of cancer

C Evangelisti, F Chiarini, F Paganelli… - … et Biophysica Acta (BBA …, 2020 - Elsevier
The introduction of therapeutics targeting specific tumor-promoting oncogenic or non-
oncogenic signaling pathways has revolutionized cancer treatment. Mechanistic (previously …

Glycogen synthase kinase 3β in cancer biology and treatment

T Domoto, M Uehara, D Bolidong, T Minamoto - Cells, 2020 - mdpi.com
Glycogen synthase kinase (GSK) 3β is a multifunctional serine/threonine protein kinase with
more than 100 substrates and interacting molecules. GSK3β is normally active in cells and …